Midatech Pharma PLC (NASDAQ:MTP) – Analysts at Zacks Investment Research issued their Q3 2017 EPS estimates for shares of Midatech Pharma in a research note issued on Monday. Zacks Investment Research analyst D. Bautz expects that the company will post earnings per share of ($0.08) for the quarter. Zacks Investment Research also issued estimates for Midatech Pharma’s Q4 2017 earnings at ($0.09) EPS, FY2017 earnings at ($0.41) EPS, FY2018 earnings at ($0.32) EPS and FY2019 earnings at ($0.32) EPS.

Midatech Pharma (NASDAQ:MTP) opened at $1.25 on Thursday. The company has a quick ratio of 1.49, a current ratio of 1.62 and a debt-to-equity ratio of 0.03. Midatech Pharma has a 12-month low of $1.00 and a 12-month high of $3.65.

ILLEGAL ACTIVITY WARNING: “Midatech Pharma PLC (MTP) to Post Q3 2017 Earnings of ($0.08) Per Share, Zacks Investment Research Forecasts” was posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/11/30/midatech-pharma-plc-mtp-to-post-q3-2017-earnings-of-0-08-per-share-zacks-investment-research-forecasts.html.

Midatech Pharma Company Profile

Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company’s segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms.

Receive News & Ratings for Midatech Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.